MacroGenics, Inc.

NasdaqGS:MGNX Stock Report

Market Cap: US$204.0m

MacroGenics Management

Management criteria checks 3/4

MacroGenics' CEO is Scott Koenig, appointed in Sep 2001, has a tenure of 23.33 years. total yearly compensation is $3.71M, comprised of 19% salary and 81% bonuses, including company stock and options. directly owns 2.07% of the company’s shares, worth $4.22M. The average tenure of the management team and the board of directors is 8 years and 7.6 years respectively.

Key information

Scott Koenig

Chief executive officer

US$3.7m

Total compensation

CEO salary percentage19.0%
CEO tenure23.3yrs
CEO ownership2.1%
Management average tenure8yrs
Board average tenure7.6yrs

Recent management updates

Recent updates

MacroGenics: A Productive Biotech With Growing Potential - Still Not A Buy

Dec 05

Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts

Aug 01
Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts

MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Jul 30
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

Jul 12
We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues

May 13
MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues

MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)

May 13

MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024

Apr 05

MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Feb 28
MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

MacroGenics: Trying To Build A Better Everything

Feb 15

There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues

Jan 09
There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues

Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price

May 17
Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price

Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

Mar 11
Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely

Jan 25
Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely

Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

Oct 25
Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

MacroGenics: No Near-Term Catalysts

Oct 11

Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics

Sep 02

MacroGenics Q2 2022 Earnings Preview

Aug 05

Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky

Jul 25
Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky

MacroGenics halts mid-stage head and neck cancer study after fatalities

Jul 11

The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically

May 09
The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically

We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

Apr 12
We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

CEO Compensation Analysis

How has Scott Koenig's remuneration changed compared to MacroGenics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$98m

Jun 30 2024n/an/a

-US$136m

Mar 31 2024n/an/a

-US$23m

Dec 31 2023US$4mUS$705k

-US$9m

Sep 30 2023n/an/a

US$50m

Jun 30 2023n/an/a

US$7m

Mar 31 2023n/an/a

-US$91m

Dec 31 2022US$5mUS$673k

-US$120m

Sep 30 2022n/an/a

-US$191m

Jun 30 2022n/an/a

-US$219m

Mar 31 2022n/an/a

-US$217m

Dec 31 2021US$5mUS$651k

-US$202m

Sep 30 2021n/an/a

-US$146m

Jun 30 2021n/an/a

-US$129m

Mar 31 2021n/an/a

-US$136m

Dec 31 2020US$3mUS$656k

-US$130m

Sep 30 2020n/an/a

-US$158m

Jun 30 2020n/an/a

-US$167m

Mar 31 2020n/an/a

-US$152m

Dec 31 2019US$5mUS$590k

-US$152m

Sep 30 2019n/an/a

-US$166m

Jun 30 2019n/an/a

-US$155m

Mar 31 2019n/an/a

-US$167m

Dec 31 2018US$5mUS$599k

-US$171m

Compensation vs Market: Scott's total compensation ($USD3.71M) is above average for companies of similar size in the US market ($USD1.38M).

Compensation vs Earnings: Scott's compensation has been consistent with company performance over the past year.

CEO

Scott Koenig (72 yo)

23.3yrs

Tenure

US$3,705,825

Compensation

Dr. Scott Koenig, M.D., Ph D., has been the President and Chief Executive Officer of Macrogenics, Inc. since September 2001. Dr. Koenig is Co-Founder of Macrogenics.He served as Senior Vice President of R...

Leadership Team

NamePositionTenureCompensationOwnership
Scott Koenig
President23.3yrsUS$3.71m2.07%
$ 4.2m
James Karrels
Senior VP16.7yrsUS$1.58m0.27%
$ 557.2k
Stephen Eck
Senior VP of Clinical Development & Chief Medical Officer4.5yrsUS$1.75m0.016%
$ 31.8k
Eric Risser
Chief Operating Officer2.9yrsUS$1.92m0.062%
$ 126.4k
Thomas Spitznagel
Senior Vice President of Technical Operations2.2yrsUS$1.88m0.013%
$ 27.0k
Ezio Bonvini
Senior VP of Research & Chief Scientific Officer8.3yrsUS$2.29m0.16%
$ 327.9k
Jeffrey Peters
Senior VP7.6yrsno datano data
Lynn Cilinski
VP, Controller & Treasurer21.3yrsno data0.0099%
$ 20.2k

8.0yrs

Average Tenure

61.5yo

Average Age

Experienced Management: MGNX's management team is seasoned and experienced (8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Scott Koenig
President23.3yrsUS$3.71m2.07%
$ 4.2m
David Stump
Independent Director11.3yrsUS$160.75k0.0072%
$ 14.6k
Federica O'Brien
Independent Director3.9yrsUS$152.00k0.0072%
$ 14.6k
Edward Hurwitz
Independent Director20.3yrsUS$147.63k0.060%
$ 122.1k
Margaret Liu
Independent Director2yrsUS$318.32k0.0072%
$ 14.6k
William Heiden
Independent Chairman of the Board2.7yrsUS$180.13k0.0072%
$ 14.6k
Meenu Chhabra Karson
Independent Director2yrsUS$335.41k0.0072%
$ 14.6k
Scott Jackson
Independent Director8yrsUS$167.63k0.0072%
$ 14.6k
Jay Siegel
Independent Director7.2yrsUS$167.21k0.0072%
$ 14.6k
Karen Jean Ferrante
Independent Director8yrsUS$135.75k0.0072%
$ 14.6k

7.6yrs

Average Tenure

66yo

Average Age

Experienced Board: MGNX's board of directors are considered experienced (7.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 03:31
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MacroGenics, Inc. is covered by 25 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Etzer DaroutBMO Capital Markets Equity Research
Stephen V. ByrneBofA Global Research